Embryonic MicroRNA-369 Controls Metabolic Splicing Factors and Urges Cellular Reprograming

• Masamitsu Konno,

  Affiliation Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Jun Koseki,

  Affiliation Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Koichi Kawamoto,

  Affiliations Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Naohiro Nishida,

  Affiliation Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Hidetoshi Matsui,

  Affiliation Faculty of Science, Kyushu University, Fukuoka, 819–0395, Japan

  ⨯
• Dyah Laksmi Dewi,

  Affiliations Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Miyuki Ozaki,

  Affiliation Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Yuko Noguchi,

  Affiliation Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Koshi Mimori,

  Affiliation Kyushu University, Department of Molecular and Surgical Oncology, Tsurumihara 4546, Beppu, Ohita, 874–0838, Japan

  ⨯
• Noriko Gotoh,

  Affiliation Division of Cancer Cell Biology, Cancer Research Institute of Kanazawa University, Kakuma-machi, Kanazawa, 920–1192, Japan

  ⨯
• Nobuhiro Tanuma,

  Affiliation Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, 981–1293, Japan

  ⨯
• Hiroshi Shima,

  Affiliation Division of Cancer Chemotherapy, Miyagi Cancer Center Research Institute, Natori, 981–1293, Japan

  ⨯
• Yuichiro Doki,

  Affiliations Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Masaki Mori ,

  Contributed equally to this work with: Masaki Mori, Hideshi Ishii

  * E-mail: hishii@gesurg.med.osaka-u.ac.jp (HI); mmori@gesurg.med.osaka-u.ac.jp (MM)

  Affiliations Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯
• Hideshi Ishii

  Contributed equally to this work with: Masaki Mori, Hideshi Ishii

  * E-mail: hishii@gesurg.med.osaka-u.ac.jp (HI); mmori@gesurg.med.osaka-u.ac.jp (MM)

  Affiliations Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan, Department of Cancer Profiling Discovery, Osaka University Graduate School of Medicine, Osaka, 565–0871, Japan

  ⨯